This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Modafinil: Mischaracterization

Stefan P. Kruszewski, MD, and Steven G. Klotz, MD

Published: June 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The August 2006 supplement to the Journal, titled "New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder" (ADHD), included an article of the same title by Joseph Biederman, M.D.1 The supplement, underwritten by "an educational grant" from Cephalon, Inc., was intended to showcase current clinical and basic scientific thoughts about ADHD, including the pharmaceutical alternatives available to treat this condition.2

The individual reports in the supplement were derived from the planning teleconference of the same title as noted above.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: